Who Owns Aurinia Pharmaceuticals Stock?
NASDAQ: AUPHHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 60.12%
- Held by insiders
- 6.74%
- Institutional holders
- 378
- Institutions 60.1%
- Insiders 6.7%
- Public and other 33.1%
Who owns Aurinia Pharmaceuticals stock?
Institutional investors own about 60.1% of Aurinia Pharmaceuticals's shares, spread across 378 institutions that file 13F reports. That level of institutional ownership is moderate. Insiders, including executives, directors and large founding shareholders, hold 6.74% of AUPH.
The largest institutional holders are Tang Capital Management, LLC (9.73%), Blackrock Inc. (6.41%) and Goldman Sachs Group Inc (4.73%). Together, the top 10 institutions control 34.3% of shares outstanding. In their latest filings, 4 of the top 10 institutions increased their AUPH positions and 4 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of AUPH
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Tang Capital Management, LLC | 13.04M | 9.73% | 0.0% |
| Blackrock Inc. | 8.59M | 6.41% | +4.8% |
| Goldman Sachs Group Inc | 6.34M | 4.73% | +12.8% |
| NEA Management Company, LLC | 3.97M | 2.96% | 0.0% |
| Arrowstreet Capital, Limited Partnership | 2.98M | 2.23% | -8.6% |
| Two Sigma Investments, LP | 2.95M | 2.20% | -14.8% |
| State Street Corporation | 2.59M | 1.93% | +0.1% |
| Marshall Wace LLP | 1.90M | 1.42% | -7.2% |
| LSV Asset Management | 1.81M | 1.35% | +67.5% |
| Morgan Stanley | 1.79M | 1.34% | -22.4% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of AUPH
| Fund | Shares | % Held |
|---|---|---|
| iShares Trust-iShares Russell 2000 ETF | 3.09M | 2.31% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.31M | 0.97% |
| iShares Trust-iShares Russell 2000 Growth ETF | 1.12M | 0.83% |
| iShares Trust-iShares Biotechnology ETF | 917.68K | 0.68% |
| VANGUARD SCOTTSDALE FUNDS-Vanguard Russell 2000 Index Fund | 683.82K | 0.51% |
| Goldman Sachs Trust-Goldman Sachs U.S. Tax-Managed Equity Fund | 541.44K | 0.40% |
| TIAA-CREF Funds-Nuveen Quant Small Cap Equity Fund | 480.65K | 0.36% |
| Fidelity Commonwealth Trust II-Fidelity Enhanced Small Cap Core ETF | 456.49K | 0.34% |
| Goldman Sachs Trust-Goldman Sachs Small Cap Value Insights Fund | 334.69K | 0.25% |
| VANGUARD WORLD FUND-Vanguard Health Care Index Fund | 323.93K | 0.24% |
Frequently asked questions
Who is the largest shareholder of Aurinia Pharmaceuticals?
Tang Capital Management, LLC is the largest institutional shareholder of AUPH, owning 9.73% of shares outstanding (13.04M shares) as of its latest 13F filing.
What percentage of Aurinia Pharmaceuticals is owned by institutions?
Institutions own about 60.1% of AUPH shares and 64.5% of the public float.
How much of Aurinia Pharmaceuticals do insiders own?
Insiders, such as officers and directors, own about 6.74% of AUPH shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.